Literature DB >> 34293382

STRIDES - STudying Risk to Improve DisparitiES in Cervical Cancer in Mississippi - Design and baseline results of a Statewide Cohort Study.

Carolann Risley1, Mary W Stewart2, Kim R Geisinger3, Laree M Hiser4, Jody C Morgan5, Kenyata J Owens6, Krishna Ayyalasomayajula7, Rhonda M Rives8, Ashish Jannela9, Dianne E Grunes10, Lei Zhang11, Mark Schiffman12, Nicolas Wentzensen13, Megan A Clarke14.   

Abstract

Cervical cancer rates in Mississippi are disproportionately high, particularly among Black individuals; yet, research in this population is lacking. We designed a statewide, racially diverse cohort of individuals undergoing cervical screening in Mississippi. Here, we report the baseline findings from this study. We included individuals aged 21 years and older undergoing cervical screening with cytology or cytology-human papillomavirus (HPV) co-testing at the Mississippi State Health Department (MSDH) and the University of Mississippi Medical Center (UMMC) (December 2017-May 2020). We collected discarded cytology specimens for future biomarker testing. Demographics and clinical results were abstracted from electronic medical records and evaluated using descriptive statistics and chi-square tests. A total of 24,796 individuals were included, with a median age of 34.8 years. The distribution of race in our cohort was 60.2% Black, 26.4% White, 7.5% other, and 5.9% missing. Approximately 15% had abnormal cytology and, among those who underwent co-testing at MSDH (n = 6,377), HPV positivity was 17.4% and did not vary significantly by race. Among HPV positives, Black individuals were significantly less likely to be HPV16/18 positive and more likely to be positive for other high-risk 12 HPV types compared to White individuals (20.5% vs. 27.9%, and 79.5% and 72.1%, respectively, p = 0.011). Our statewide cohort represents one of the largest racially diverse studies of cervical screening in the U.S. We show a high burden of abnormal cytology and HPV positivity, with significant racial differences in HPV genotype prevalence. Future studies will evaluate cervical precancer risk, HPV genotyping, and novel biomarkers in this population.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Cervical cancer screening; Disparities; HPV; Race

Mesh:

Year:  2021        PMID: 34293382      PMCID: PMC8595817          DOI: 10.1016/j.ypmed.2021.106740

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  22 in total

1.  The ATHENA HPV study underrepresents "other" high-risk HPV genotypes when compared with a diverse New York City population.

Authors:  G Ramos Rivera; S N Khader; S Lajara; K Schlesinger; D Y Goldstein; R C Naeem; M J Suhrland; A S Fox
Journal:  Cytopathology       Date:  2017-07-21       Impact factor: 2.073

2.  Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.

Authors:  Julia C Gage; William C Hunt; Mark Schiffman; Hormuzd A Katki; Li A Cheung; Orrin Myers; Jack Cuzick; Nicolas Wentzensen; Walter Kinney; Philip E Castle; Cosette M Wheeler
Journal:  Obstet Gynecol       Date:  2016-12       Impact factor: 7.661

3.  Racial/ethnic differences in HPV 16/18 genotypes and integration status among women with a history of cytological abnormalities.

Authors:  J R Montealegre; E C Peckham-Gregory; D Marquez-Do; L Dillon; M Guillaud; K Adler-Storthz; M Follen; M E Scheurer
Journal:  Gynecol Oncol       Date:  2017-12-21       Impact factor: 5.482

4.  Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer.

Authors:  Peng Guan; Rebecca Howell-Jones; Ni Li; Laia Bruni; Silvia de Sanjosé; Silvia Franceschi; Gary M Clifford
Journal:  Int J Cancer       Date:  2012-03-20       Impact factor: 7.396

5.  Racial differences in HPV type 16 prevalence in women with ASCUS of the uterine cervix.

Authors:  Carolann Risley; Megan A Clarke; Kim R Geisinger; Mary W Stewart; Lei Zhang; Kim W Hoover; Laree M Hiser; Kenyata Owens; Maria DeMarco; Mark Schiffman; Nicolas Wentzensen
Journal:  Cancer Cytopathol       Date:  2020-04-03       Impact factor: 5.284

6.  Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty.

Authors:  Linda M Niccolai; Chelsea Russ; Pamela J Julian; Susan Hariri; John Sinard; James I Meek; Vanessa McBride; Lauri E Markowitz; Elizabeth R Unger; James L Hadler; Lynn E Sosa
Journal:  Cancer       Date:  2013-05-09       Impact factor: 6.860

7.  HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA.

Authors:  Adriana C Vidal; Jennifer S Smith; Fidel Valea; Rex Bentley; Maggie Gradison; Kimberly S H Yarnall; Anne Ford; Francine Overcash; Kathy Grant; Susan K Murphy; Cathrine Hoyo
Journal:  Cancer Causes Control       Date:  2014-06-14       Impact factor: 2.506

8.  Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.

Authors:  Maria Demarco; Thomas S Lorey; Barbara Fetterman; Li C Cheung; Richard S Guido; Nicolas Wentzensen; Walter K Kinney; Nancy E Poitras; Brian Befano; Philip E Castle; Mark Schiffman
Journal:  J Low Genit Tract Dis       Date:  2017-10       Impact factor: 1.925

9.  Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women.

Authors:  Gary M Clifford; Vanessa Tenet; Damien Georges; Laia Alemany; Miquel Angel Pavón; Zigui Chen; Meredith Yeager; Michael Cullen; Joseph F Boland; Sara Bass; Mia Steinberg; Tina Raine-Bennett; Thomas Lorey; Nicolas Wentzensen; Joan Walker; Rosemary Zuna; Mark Schiffman; Lisa Mirabello
Journal:  Papillomavirus Res       Date:  2019-02-06

10.  Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines.

Authors:  Didem Egemen; Li C Cheung; Xiaojian Chen; Maria Demarco; Rebecca B Perkins; Walter Kinney; Nancy Poitras; Brian Befano; Alexander Locke; Richard S Guido; Amy L Wiser; Julia C Gage; Hormuzd A Katki; Nicolas Wentzensen; Philip E Castle; Mark Schiffman; Thomas S Lorey
Journal:  J Low Genit Tract Dis       Date:  2020-04       Impact factor: 3.842

View more
  2 in total

1.  Human papilloma virus vaccination and cervical cancer screening coverage in managed care plans - United States, 2018.

Authors:  Thomas B Richards; Megan C Lindley; Sepheen C Byron; Mona Saraiya
Journal:  Prev Med       Date:  2022-03-10       Impact factor: 4.018

2.  Age-specific prevalence of human papillomavirus and abnormal cytology at baseline in a diverse statewide prospective cohort of individuals undergoing cervical cancer screening in Mississippi.

Authors:  Megan A Clarke; Carolann Risley; Mary W Stewart; Kim R Geisinger; Laree M Hiser; Jody C Morgan; Kenyata J Owens; Krishna Ayyalasomayajula; Rhonda M Rives; Ashish Jannela; Dianne E Grunes; Lei Zhang; Mark Schiffman; Sarah Wagner; Joseph Boland; Sara Bass; Nicolas Wentzensen
Journal:  Cancer Med       Date:  2021-11-03       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.